UroGen Pharma: Funding, Investors & Team (Sep 2026)

UroGen Pharma (formerly Theracoat ) (“UroGen” or “the Company”) is a clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies with a focus on uro-oncology. The Company has an innovative and broad pipeline of product candidates that it believes can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. The lead product candidates, MitoGel and VesiGel, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant, post-surgery, therapy. The Company’s clinical stage pipeline includes Vesimune, its proprietary immunotherapy product candidate for the treatment of high-grade non-muscle invasive bladder cancer. In addition, BotuGel is a proprietary novel RTGel-based formulation of BOTOX, a branded drug, that it believes can potentially serve as an effective treatment option for patients suffering from overactive bladder. UroGen has licensed the worldwide rights to BotuGel to Allergan Pharmaceuticals International Limited, or Allergan, a wholly owned subsidiary of Allergan plc, which plans to commence a Phase 2 clinical trial of BotuGel.

UroGen Pharma has raised $100M across 1 round on record. The most recent is a Post-IPO Debt of $100M announced in Mar 2022.

UroGen Pharma's most recent funding round on record is a Post-IPO Debt of $100M, announced in Mar 2022.

Liz Barrett is listed as CEO at UroGen Pharma.

UroGen Pharma is based in New York, United States.

UroGen Pharma is in the 101-250 employee band.

UroGen Pharma's latest round of $100M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.